The cash won't stop for Exscientia as it makes a $300M+ Nasdaq debut
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
An AI biotech with little human data — but lots of hype — is once again drowning in cash.
Exscientia priced its IPO late Thursday evening, announcing it pulled in $304.7 million with the raise. The public debut marks Exscientia’s third nine-figure raise of the year, after the biotech expanded its Series C to $100 million in March and raised more than half a billion dollars in a pair of financings in April. Exscientia shares will begin trading Friday at $22 apiece under the ticker $EXAI.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.